Charles Schwab Investment Management Inc. Decreases Stake in Invivyd, Inc. (NASDAQ:IVVD)

Charles Schwab Investment Management Inc. decreased its holdings in Invivyd, Inc. (NASDAQ:IVVD) by 11.4% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 186,680 shares of the company’s stock after selling 24,069 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Invivyd were worth $83,000 at the end of the most recent reporting period.

Separately, State Street Corp increased its position in shares of Invivyd by 3.7% in the third quarter. State Street Corp now owns 1,018,640 shares of the company’s stock worth $1,039,000 after acquiring an additional 35,904 shares in the last quarter. 70.36% of the stock is owned by hedge funds and other institutional investors.

Invivyd Trading Down 10.8 %

IVVD opened at $0.54 on Wednesday. Invivyd, Inc. has a twelve month low of $0.35 and a twelve month high of $4.24. The firm has a market cap of $64.78 million, a price-to-earnings ratio of -0.28 and a beta of 0.09. The company has a fifty day simple moving average of $1.01 and a 200 day simple moving average of $0.85.

Invivyd (NASDAQ:IVVD) last announced its earnings results on Thursday, March 20th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.10. The business had revenue of $13.80 million for the quarter, compared to analyst estimates of $13.57 million. On average, analysts forecast that Invivyd, Inc. will post -1.64 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

IVVD has been the topic of several recent research reports. D. Boral Capital restated a “buy” rating and set a $9.00 target price on shares of Invivyd in a report on Thursday, March 20th. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Invivyd in a research note on Wednesday, March 26th. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $7.89.

Invivyd Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.